603233.SH
DaShenLin Pharmaceutical Group Co., Ltd.
SSE · Healthcare · Biotechnology · CN
CNY 17.36
−1.70%Next report
Analyst consensus
- Next report date
- Oct 29, 2026
- EPS estimate
- CNY 0.34
- Revenue estimate
- CNY 7.4B
Latest reported
- Last report date
- Aug 24, 2026
- EPS actual
- CNY 0.36
- EPS estimate
- CNY 0.30
- Revenue actual
- CNY 6.9B
- Revenue estimate
- CNY 7.4B
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 1
- EPS misses (12Q)
- 0
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +20.8%
- Revenue beats (12Q)
- 0
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 24, 2026 | CNY 0.30 | CNY 0.36 | Beat 20.82% | CNY 6.9B |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Oct 29, 2026